摘要
目的探讨急性心肌梗死(AMI)患者经皮冠脉介入术(PCI)后无复流采用替罗非班治疗的临床效果。方法选取我院2015年1月至2017年1月收治的100例PCI后出现无复流的AMI患者,采用随机数字表法分为观察组和对照组各50例,观察组给予替罗非班治疗,对照组给予低分子肝素治疗,对比两组治疗前后的TIMI血流分级、校正的TIMI计帧数(CTFC)、2个月后的不良心血管事件(MACE)发生率。结果治疗前,观察组和对照组的TIMI血流分级差异无统计学意义(P>0. 05);治疗后,观察组的TIMI血流分级优于对照组,差异有统计学意义(P<0. 05);治疗前,观察组和对照组的CTFC帧数差异无统计学意义(P>0. 05);治疗后,观察组的CTFC帧数低于对照组,差异有统计学意义(P<0. 05);两组患者的CTFC帧数较治疗前均显著的降低,差异均有统计学意义(P<0. 05);观察组的MACE发生率14. 00%低于对照组的32. 00%,差异有统计学意义(P<0. 05)。结论 AMI患者PCI后无复流采用替罗非班治疗有利于恢复心肌灌注,降低MACE发生率。
Objective To investigate the clinical effect of tirofiban in patients with acute myocardial infarction(AMI)without reflow after underwent percutaneous coronary intervention(PCI).Methods 100 patientswith AMI without reflow after PCI,from January 2015 to January 2017 in our hospital,were divided into observation group and control group by random number table method,and each group contained 50 cases.The observation group was treated with tirofiban,andthe control group was treated with low molecular weight heparin.The incidence of TIMI blood flow grades,corrected TIMI frame count(CTFC)and adverse cardiovascular events after 2 months(MACE)were compared between the two groups.Results Before treatment,there was no significant difference in TIMI blood flow grades in the two group(P>0.05).After treatment,the TIMI blood flow gradesin the observation group was better than that in the control group,statistically significant(P<0.05).Before treatment,there was no significant difference in the number of CTFC frames between the two group(P>0.05).After treatment,the number of CTFC frames in the observation group was lower than that in the control group,statistically significant(P<0.05).The number of CTFC frames in the two group was significantly lower than that before treatment,a statistically significant(P<0.05).The incidence of MACE in the observation group(14.00%)was lower than that in the control group(32.00%),statistically significant(P<0.05).Conclusion The use of tirofiban in patients with AMI after PCI is beneficial to restore myocardial perfusion and reduce the incidence of MACE.
作者
闫杰松
李志勇
Yan Jiesong;Li Zhiyong(The 3201 Hospital,Hanzhong,Shanxi 723000,China)
出处
《四川医学》
CAS
2019年第4期394-397,共4页
Sichuan Medical Journal
